Screen suppliers for sterile, oncology, controlled substance, and high-potency capability. The capability-filtered supplier shortlist for complex APIs.
The catalog carries 953 sterile-capable plants and 431 controlled-substance handlers globally. For palbociclib (oncology API, sterile-compatible), the qualifiable Indian cohort includes Gland Pharma, Intas, Indoco Remedies, and NATCO Pharma. The shortlist crosses three filters: sterile or oncology capability, active FDA Type II DMF coverage, and an NAI or VAI-improving inspection class.
| # | Plant | Region | Capability | Accreditation depth | Inspection |
|---|---|---|---|---|---|
| 1 | Gland Pharma Hyderabad | IN · Hyderabad | 3 sterile facilities | FDA + EDQM + WHO-PQ overlap | NAI |
| 2 | Intas Pharmaceuticals Ahmedabad | IN · Ahmedabad | 2 sterile facilities | FDA + EDQM overlap | VAI |
| 3 | NATCO Pharma Rangareddy | IN · Rangareddy | 1 sterile facility | FDA + EDQM overlap | NAI |
| 4 | Sun Pharma Halol | IN · Halol | 2 sterile facilities | FDA + EDQM overlap | OAI |
| 5 | Cipla Salcette | IN · Goa | 1 sterile facility | FDA + EDQM overlap | VAI |
| 6 | Indoco Remedies Verna | IN · Goa | 1 sterile facility | FDA + EDQM overlap | NAI |
| 7 | Eugia Pharma Specialities | IN · Bhiwadi | 1 sterile facility | FDA + EDQM overlap | VAI |
| 8 | Caplin Steriles | IN · Gummidipoondi | 1 sterile facility | FDA + EDQM overlap | NAI |
Sterile, oncology, high-potency, controlled substance, or specific dosage forms. The AI agent pulls every plant in the capability catalog matching the filter.
Where a specific molecule is named, plants with active DMFs on the molecule plus the required capability surface together. Accreditation chips and inspection class join at the schema layer.
Citation-anchored brief with the qualifying plants, capability chip, accreditation depth, and a chip showing recent inspection class.
An onco-API needs oncology and often sterile capability at the plant. Without the filter, the supplier shortlist is full of plants that can't actually run the chemistry.
Capability without accreditation is academic; FDA registration plus EDQM CEP makes the plant commercially actionable. The chip shows the overlap inline.
A sterile plant in OAI is high-risk. Surfacing inspection class on the shortlist prevents speculative qualification work on a plant under enforcement.
Capability catalog refreshes monthly with new attestations and FDA inspection notes. Coverage transitions propagate on the next refresh.
A real chat thread in PharmaDB. Type a question, the AI agent runs the tools, the answer lands as a saveable note.
pharmagraph_query Plant capability catalog · counts per category and overlap, live snapshot.
Specialised manufacturing capability is the hard filter for complex APIs. PharmaDB joins the plant capability catalog to accreditation coverage and inspection class so the capability shortlist is one query, not a multi-source spreadsheet. The view rests on plant_capabilities, plant_accreditations, and inspections. Refresh cadence is monthly.
The current catalog covers sterile manufacturing and controlled substance handling at the plant level. Oncology, high-potency, peptide synthesis, and dosage-form-specific capabilities are tracked as attribute extensions on the same `plant_capabilities` table. New capability codes ingest as new attestation sources publish.
FDA inspection narratives, EDQM CEP scope documents, plant accreditation registers, and primary supplier attestations. PharmaDB carries a confidence flag per capability code; the highest confidence is reserved for regulator-published attestations.
Peptide synthesis is its own capability code; biosimilars surface under bioprocessing capability when the plant has fermentation and downstream processing capacity. The headline cohort is small-molecule sterile and controlled substance, but the catalog extends to biologics where the attestation exists.
Capability does not override compliance. Halol carries strong sterile capacity but the OAI inspection class moves it out of the immediate qualifiable shortlist. The chip surfaces both signals so the buyer's decision is informed.
Yes. Sterile FDF is a distinct capability code in the catalog. FDF capability layers on top of API capability for plants running both. The molecule-level join then constrains the cohort to plants that actually manufacture the relevant FDF.
Monthly. Capability catalog refreshes monthly as new attestations publish. The catalog row carries an as-of timestamp on every result page.
Bring the molecule, the lane, or the supplier you're sourcing this week. The AI agent runs it on PharmaDB in 30 minutes. You keep the brief.